Chin. J. Org. Chem. ›› 2018, Vol. 38 ›› Issue (7): 1596-1607.DOI: 10.6023/cjoc201801022 Previous Articles     Next Articles



赵文姣a,b, 孙德群a,b   

  1. a 山东大学(威海)海洋学院 威海 264209;
    b 西南科技大学生命科学与工程学院 绵阳 621010
  • 收稿日期:2018-01-16 修回日期:2018-03-26 发布日期:2018-04-12
  • 通讯作者: 孙德群
  • 基金资助:


Novel Drug Development Process of Anti-Alzheimer Targeted to Glycogen Synthase Kinase-3

Zhao Wenjiaoa,b, Sun Dequna,b   

  1. a Marine College, Shandong University at Weihai, Weihai 264209;
    b School of Life Science and Engineering, Southwest University of Science and Technology, Mianyang 621010
  • Received:2018-01-16 Revised:2018-03-26 Published:2018-04-12
  • Contact: 10.6023/cjoc201801022
  • Supported by:

    Project supported by the National Natural Science Foundation of China (No. 81773560).

Alzheimer's disease is the leading cause of dementia, which can endanger devastating damage to memory and cognition of the elderly and eventually lead to death. Over expression of glycogen synthase kinase-3 (GSK-3) is closely related to the development and progression of Alzheimer's disease, and has become a hot field for the development of therapies for Alzheimer's disease. The GSK-3 inhibitors reported in recent five years, mainly including ATP competitive inhibitors, non-ATP competitive inhibitors, substrate competitive inhibitors, allosteric inhibitors, irreversible inhibitors are summarized and natural products, furthermore, the source, chemical structure and mechanism about GSK-3 inhibitors are introduced. Research prospects in this field are also discussed.

Key words: Alzheimer's disease, glycogen synthase kinase-3 (GSK-3), amyloid plaque, neurofibrillary tangle